My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

336.19 -3.18 (-0.94%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

A Bearish Sign Appears On Alnylam Pharmaceuticals's Chart ↗

April 11, 2023

Via Benzinga

Here's How Much $100 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today ↗

April 05, 2023

Via Benzinga

Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots ↗

April 04, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023 ↗

March 21, 2023

Via Benzinga

Analyst Ratings for Alnylam Pharmaceuticals ↗

March 21, 2023

Via Benzinga

Alnylam Pharmaceuticals's Return On Capital Employed Insights ↗

February 27, 2023

Via Benzinga

Analyst Ratings for Alnylam Pharmaceuticals ↗

February 24, 2023

Via Benzinga

Alnylam's Lumasiran Scores Expanded FDA Approval For Ultra Rare Genetic Disease ↗

October 07, 2022

Via Benzinga

Analyst Ratings for Alnylam Pharmaceuticals ↗

October 03, 2022

Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter:

Via Benzinga

3 Growth Stocks That Could Disrupt the Healthcare Industry ↗

March 13, 2023

These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time.

Via InvestorPlace

Looking Into Alnylam Pharmaceuticals's Recent Short Interest ↗

March 03, 2023

Alnylam Pharmaceuticals's (NASDAQ:ALNY) short percent of float has fallen 5.3% since its last report. The company recently reported that it has 5.10 million shares sold short, which is 4.82% of all...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023 ↗

February 21, 2023

Via Benzinga

Alnylam Reinforces Patisiran Data In Stiff Heart Disorder Before Heading For FDA Approval ↗

October 03, 2022

Via Benzinga

Five Best And Worst Performing Healthcare Stocks In December 2022 ↗

January 22, 2023

Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst...

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023 ↗

January 18, 2023

Via Benzinga

3 Growth Stocks That Could Rocket Higher in 2023 ↗

January 06, 2023

Upcoming binary events could push these stocks to new all-time highs.

Via The Motley Fool

Meta To Rally Over 29%? Here Are 10 Other Price Target Changes For Friday ↗

December 16, 2022

Via Benzinga

Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims ↗

December 06, 2022

Via Benzinga

Looking Into Alnylam Pharmaceuticals's Return On Capital Employed ↗

November 02, 2022

Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q3 sales of $264.31 million. Earnings fell to a loss of $405.92 million, resulting in a 46.33% decrease from last quarter.

Via Benzinga

What 11 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗

November 02, 2022

Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:

Via Benzinga

Alnylam Scraps Interim Analysis For Heart Disease Trial, Rethinks Plans For Another Rare Disorder Program ↗

October 27, 2022

Via Benzinga

Alnylam Pharmaceuticals: Q3 Earnings Insights ↗

October 27, 2022

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q3 earnings results on Thursday, October 27, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures? ↗

October 20, 2022

Despite enthusiasm in some camps, the risk of potential cures clouds market projections.

Via Investor's Business Daily

Where Alnylam Pharmaceuticals Stands With Analysts ↗

October 13, 2022

Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:

Via Benzinga

Roblox To $51? Plus Deutsche Bank Slashes PT On Deere & Company ↗

October 13, 2022

Via Benzinga

3 Top Biotech Stocks Defying the Bear Market ↗

October 11, 2022

Bear market, shmear market. These biotech stocks are soaring despite the market downturn.

Via The Motley Fool

Where Alnylam Pharmaceuticals Stands With Analysts ↗

October 03, 2022

Over the past 3 months, 12 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

What 12 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗

October 03, 2022

Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter:

Via Benzinga

AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know ↗

October 02, 2022

Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 22, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.